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Detecting biomarkers from complex sample solutions is the key objective of molecular diagnostics. 
Being able to do so in a simple approach that does not require laborious sample preparation, 
sophisticated equipment and trained staff is vital for point-of-care applications. Here, we report on the 
specific detection of the breast cancer biomarker sHER2 directly from serum and saliva samples by a 
nanorod-based homogeneous biosensing approach, which is easy to operate as it only requires mixing 
of the samples with the nanorod probes. By careful nanorod surface engineering and homogeneous 
assay design, we demonstrate that the formation of a protein corona around the nanoparticles does 
not limit the applicability of our detection method, but on the contrary enables us to conduct in-situ 
reference measurements, thus further strengthening the point-of-care applicability of our method. 
Making use of sandwich assays on top of the nanorods, we obtain a limit of detection of 110 pM and 470 
pM in 10-fold diluted spiked saliva and serum samples, respectively. In conclusion, our results open up 
numerous applications in direct protein biomarker quantification, specifically in point-of-care settings 
where resources are limited and ease-of-use is of essence.
Molecular diagnostics employed for the diagnosis and prognostics of a wide range of diseases is based on the 
detection of biomarkers in complex sample solutions and is of enormous scientific and clinical interest1, 2. Within 
the range of methods employed for biomarker detection, homogenous measurement techniques are of special 
relevance for point-of-care (PoC) testing settings, as they allow for omitting complex sample preparation steps. 
Thus, the time for sample analysis may be reduced, whilst ensuring at the same time maximal ease-of-use3. Here, 
magnetic nanoparticles play a major role due to their added capability of magnetic manipulation, which can 
be exploited, for example, to accelerate binding processes or to enhance the signal to noise ratio4. Alternative 
non-magnetic nanoparticle-based bio sensing techniques include surface-enhanced Raman spectroscopy5, 6 or 
methods relying on fluorescent nanoparticle properties7. It has been shown that the combination of nanopar-
ticle labels and surface-enhanced Raman spectroscopy allows to detect various biomarkers in complex sample 
solutions8, 9.
In the present article, we show the applicability of our previously introduced magnetic nanoparticle-based 
homogeneous measurement principle to molecular diagnostics in complex samples, i.e. serum and saliva sam-
ples. The method relies on changes of the hydrodynamic nanoparticle volume upon analyte molecule binding. To 
that end, antibody-functionalized magnetic nanorods (‘nanoprobes’) are excited in solution by a rotating mag-
netic field (RMF), which results in a rotational nanoprobe motion. The hydrodynamic volume of the nanoprobes 
induces a rotational drag torque with the result that the nanoprobes lag behind the RMF by a characteristic phase 
lag. Binding of the antigen causes an increase of the hydrodynamic nanoprobe volume, which can be observed 
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directly via a change of the phase lag. This effect can be further enhanced by also adding secondary antibodies to 
form a sandwich-type immunoassay on top of the nanoprobe surface. The phase lag is determined optically by 
measurements of the actual nanoprobe alignment. This is made possible by the elongated nanoparticle geometry 
that causes anisotropic absorption and scattering. When applying linearly polarized incident light, this effect 
allows for deducing the actual nanoprobe orientation in the sample solution via transmission measurements. By 
correlating the measured actual nanoprobe orientation with the momentary vector of the applied RMF, the phase 
lag angle can be determined, and our signal is defined by the change in phase lag angle (Δα) between the sample 
and a suitable reference 10–12. Next to the inherent advantages of homogenous magnetic nanoparticle-based 
measurement methods, we show that our method is capable of determining quantitative biomarker concentration 
levels in complex samples by in-situ referencing.
As model protein we have chosen the soluble domain of the human epidermal growth factor receptor 2 - 
sHER2, which is the extracellular domain of HER2, a receptor-like tyrosine kinase that is reported to be involved 
in several types of human carcinomas13. The extracellular sHER2 protein is shed into the blood stream so that it 
can be found in serum as well as in saliva samples, currently being mainly of interest for the diagnosis as well as 
for the prognosis of breast cancer14, 15. Currently, the clinical cut-off value for sHER2 in serum is 170 pM14, while 
the clinical cut-off value for saliva is one order of magnitude below the serum value15.
In the following sections, we describe the measures that are taken to detect the sHER2 analyte protein in com-
plex samples of serum and saliva, which were spiked with sHER2. These measures include the right choice of type 
and concentration of secondary antibodies as well as the dilution factor of the complex sample solutions. Finally, 
we conclude by summarizing the major results and by giving an outlook on how to further apply and improve the 
measurement method.
Results and Discussion
Simplest mix-and-measure detection of sHER2 analyte in complex solution spiked with sHER2 could be executed 
by adding the nanoprobes to the sample solution, followed by determining the phase lag difference Δα with 
respect to a reference sample. To that end, initial measurements have been executed in 10-fold diluted serum 
samples. What at a first glance seemed to be a promising measurement approach did not result in an analyte 
molecule concentration-dependent signal (see Supplementary Fig. S1). This we attribute to the formation of a 
protein corona in complex samples surrounding the nanoprobe surface16, which screens the measurement effect 
of bound analyte molecules. Hence, additional measures had to be taken to gain specificity. This can be achieved 
by employing secondary antibodies (2nd Abs) in a sandwich-type immunoassay format (see sketch in Fig. 1a). The 
2nd Abs attach to the nanoprobe-bound analyte molecules, and, when extending the protein corona thickness, 
retrieve the concentration dependent measurement signal that has previously been observed for spiking analyte 
molecules alone into buffer solutions10. The exact composition and structure of the protein corona formed on 
top of the nanoprobes cannot be answered here, while in principle we assume a single layer of adsorbed proteins. 
Detailed studies applying exactly the same conditions will be required to gain a deep understanding of the funda-
mental principles of protein corona formation for our nanoprobes.
To characterize the effect of adding 2nd Abs to our measurement technique, we first determined their optimal 
concentration. Figure 1b shows the dependence of the measurement signal in buffer solution of nanoprobes 
functionalized by the primary antibody Ab-a on adding varying concentration of the secondary antibody Ab-b 
for two distinct concentrations of sHER2 analyte molecules (2 nM and 8 nM). Clearly, the signal increased for 
rising 2nd Ab concentrations up to a saturation level, which correlates with the concentration of analyte molecules. 
Figure 1. Signal dependence on secondary antibody concentration. (a) Sketch of the nanorod (NR) based 
sandwich-type immunoassay employing primary (1st) and secondary (2nd) antibodies (Ab); (b) Phase lag 
difference Δα in measurement buffer solution for two fixed concentrations of sHER2 analyte molecules (2 and 
8 nM) in dependence of the added concentration of 2nd antibodies.
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Specifically, the signal saturated for both analyte concentrations when adding at least five times higher 2nd Ab 
concentrations. The addition of 2nd Abs without sHER2 did not result in a measurable signal.
In an actual assay recipe, a fixed concentration of added 2nd Abs needs to be selected. Here, our chosen 2nd Ab 
concentration of 25 nM allows maximal and roughly linear signal amplification within a measurement range up 
to about 5 nM sHER2 (the limit was obtained from the observed signal saturation at about five times the analyte 
molecule concentration).
Furthermore, the assay can be optimized by carefully choosing the best suited antibody pairs. To that end, we 
tested all combinations of Ab-a and Ab-b as primary and secondary antibodies. Corresponding measurement 
results are shown in the Supplementary Table S1 and indicate that the application of Ab-b as both primary and 
secondary antibody resulted in maximal measurement signal (case A). This is due to the polyclonal nature of 
Ab-b and the associated higher binding affinity compared to monoclonal antibodies. Consequently, when Ab-a 
is applied as primary antibody instead of Ab-b (case B), less antigen binds to the nanoprobes, resulting in lower 
signal on adding Ab-b as secondary antibody (case B vs. case A). As expected, as only a single epitope is targeted, 
the application of the monoclonal antibody type Ab-a as both primary and secondary antibody resulted in the 
lowest measurement signal (case D). When combining Ab-a and Ab-b, the signal was substantially larger for 
applying Ab-a as primary and Ab-b as secondary antibody (case B) as vice versa (case C). This we attribute to 
steric hindrance of the epitope targeted by the monoclonal Ab-a when the antigen is bound to the nanoprobes via 
primary antibody Ab-b. Based on these results, all subsequent measurements were carried out with Ab-b both as 
primary and secondary antibody (case A).
The next aspect to be addressed in order to optimize the assay for complex sample solutions like saliva and 
serum is the determination of the optimum dilution factor. Dilution is an important aspect of our measurement 
approach as the structure and the composition of the protein corona depends on the types and the concentrations 
of the proteins present in the sample solution and, therefore, on the sample dilution17. In addition, the nanoprobe 
rotation is also influenced by the concentration of non-bound proteins in solution, thereby affecting the drag 
torque and measured phase lag18. Consequently, by adjusting the dilution factor, the measurement signal can be 
maximized. To that end, different saliva dilutions were tested. Here, we have chosen a high initial concentration 
of sHER2 of 10 nM spiked into pure saliva to ensure that the concentration after dilution remains high enough 
to be easily detected. On the other hand, the initial concentration was chosen low enough to guarantee less than 
5 nM even in low sample dilutions for optimal signal enhancement by the 2nd Abs as shown above. The obtained 
measurement signals at different dilutions of saliva are shown in Supplementary Table S2. A dilution factor of 10 
resulted in the highest measurement signal and was, thus, chosen in the following. For best possible comparability 
of serum and saliva samples, the same dilution factor was chosen also for serum samples.
Based on the information gained by the results presented above, we conducted phase lag difference meas-
urements in dependence of the analyte concentration in solutions of pure buffer, serum, and saliva. For all these 
measurement series, we determined the relevant limits of detection.
Figure 2 shows the measurement results for the sHER2 assay conducted in pure buffer solution. The phase 
lag difference signal Δα clearly increased with increasing analyte concentration up to a saturation level, and was 
substantially larger when 2nd Abs were also added. In this case, the signal saturated at about 5 nM sHER2 concen-
tration, and decreased for higher concentrations. This decrease is due to the now non-optimal ratio of 2nd Abs to 
analyte molecules (see above). The achieved limits of detection were about 400 pM for the assay without 2nd Ab 
addition and about 170 pM after addition of 2nd Abs.
Finally, we conducted assay measurements in 10-fold diluted solutions of spiked serum and saliva with 
addition of 2nd Abs. Generally, the results compared well with the ones obtained with 2nd Ab addition in buffer 
Figure 2. Phase lag difference signal Δα in pure buffer solution and its dependence on the antigen 
concentration. Measurement signal with (black curve) and without (grey curve) the addition of 2nd Abs.
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solution. Specifically, the signals again rose up to a saturation level of about 5 nM sHER2 concentration. While 
in diluted serum, we deduced a limit of detection of about 470 pM, in diluted saliva samples sHER2 could be 
detected down to about 110 pM. The reason for the better measurement sensitivity in saliva compared to serum 
we attribute to different protein composition of serum and saliva samples and the difference in total protein con-
tent15, 19. Specifically, the lower reference phase lag in saliva allowed for a larger relative phase lag increase due to 
analyte and 2nd Ab binding12. We ascribe the slightly better detection limit in diluted saliva samples compared to 
buffer solution to adsorption of tertiary proteins to the bound 2nd Abs, which further increases the signal.
Conclusions
In this work, we demonstrated that our previously introduced nanoprobe-based homogeneous biosensing 
approach is also feasible to specifically detect analyte proteins in complex sample solutions (i.e. serum and saliva). 
While in buffer solution, direct analyte quantification is possible, the formation of a protein corona in com-
plex samples screens the direct measurement signal. Consequent, the increase in hydrodynamic diameter due 
to antibody-mediated binding of target protein cannot be distinguished from non-specific adsorption (i.e. the 
formation of a protein corona). However, upon addition of secondary antibodies to the sample solution, there 
again is a specific further increase in hydrodynamic nanoprobe size, which results in a detection signal. Thus, 
what at first glance seems to be a disadvantage, can in fact be exploited to conduct in-situ reference measurements 
by simply not adding 2nd Abs, which is an important feature for PoC testing environments.
We systematically elaborated measurement conditions to determine sHER2 analyte protein directly in spiked 
complex sample solutions by establishing a homogeneous sandwich assay directly at the surface of our dispersed 
nanoprobes. Recalculated to undiluted samples, our sHER2 limit of detection currently is about 4.7 nM in serum 
and 1.1 nM in saliva, which is about one order of magnitude above the clinical cut-off value for serum14, and, 
due to the substantially lower concentration, about two orders of magnitude above the clinical cut-off value for 
saliva15. However, our results demonstrate that by advancing the nanoprobe assay conditions, the detection limit 
can still be improved substantially. For example, in buffer solution we observed a significant enhancement of the 
signal and detection limit by introducing 2nd Abs, which can be expected to further improve by applying labelled 
2nd Abs to bind large molecular weight biopolymers. In addition, while we tested some antibody combinations 
and observed a substantial effect on our measurement signal, there is a wide variety of different antibodies avail-
able to determine the best-suited pair.
In summary, for our simple mix-and-measure type homogeneous biosensor we succeeded to overcome a 
major hurdle that nanoparticle biosensors often suffer from, which concerns signal screening by protein corona 
formation. This opens up numerous applications in protein biomarker detection, specifically in PoC settings 
where resources are limited and ease-of-use is of essence.
Methods
Nanoprobe preparation. The nanoprobe preparation comprises the synthesis of bare Co nanorods (NRs), 
which were covered by a noble metal shell of Au and Pt according to already published procedures20. Afterwards, 
the NRs were transferred to aqueous solutions by over-coating them with an amphiphilic polymer as described 
earlier10, 21. The functionalization of the NRs with antibodies (Abs) was achieved by carboxy-amine linker chem-
istry. To that end, we employed EDC (N-(3-(dimethylamino)propyl)-N′-ethylcarbodiimide hydrochloride) and 
S-NHS (N-hydroxysulfosuccinimide sodium salt) at ratios of 1 × 104 EDC molecules and 3 × 104 S-NHS mole-
cules per NR. The NR concentration was determined by inductively coupled plasma mass spectrometry and by 
Figure 3. Phase lag difference signal Δα in 10-fold diluted solutions of spiked serum and saliva and its 
dependence on the antigen concentration. Measurement signal in saliva (blue curve) and in serum (red curve) 
under addition of 2nd Abs.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 4752  | DOI:10.1038/s41598-017-04970-5
the geometric NR dimensions determined by transmission electron microscopy as described elsewhere10. We 
employed a NR concentration of 730 pM and 2-(N-morpholino)-ethanesulfonic acid (MES) buffer solution at 
a concentration of 50 mM and at a pH of 5.5 throughout the whole functionalization procedure. In a first func-
tionalization step, the NRs were incubated with EDC and S-NHS for 15 min at room temperature (RT) and then 
dialyzed against MES for 30 min at RT to reduce the concentration of EDC and S-NHS. The dialysis was per-
formed with a Float-A-Lyzer G2 dialysis device with an approximate molecular weight cut-off value of 1000 kDa. 
Afterwards, the Abs diluted in MES were added at a volume comparable to the NR/EDC/S-NHS solution at a 
ratio of 200 Abs per NR, and the whole solution was incubated for 100 min at RT. Abs applied here were either 
trastuzumab in the form of the Herceptin therapeutic drug (Ab-a) or commercial HER2 antibodies (Ab-b) pur-
chased from R&D Systems under catalogue number AF1129. Here, Ab-a is a monoclonal antibody, while Ab-b 
is of polyclonal nature. In a next step, 100 bovine serum albumin molecules per NR were added, followed by 
another incubation step overnight at 4 °C to block any remaining binding sites. Finally, to remove all unbound 
reagents, the functionalized NRs were dialyzed against MES at a pH of 5.5 for 48 h at 4 °C with a change of the 
dialysis solution after 20 h.
Sample preparation and measurement conditions. The employed serum (pool of healthy male indi-
viduals) was obtained commercially from Sigma-Aldrich (product number H4522), while unstimulated whole 
saliva was collected in the morning from a single healthy male individual who refrained from eating before sam-
ple taking. The non-invasive saliva sample has been donated by a staff scientist of AIT following informed consent 
and approval by the Local Ethics Committee of the City of Vienna22. All methods were performed in accordance 
with the relevant guidelines and regulations. Saliva was filtered by a Whatman glass fibre syringe filter with a 
nominal pore size of 0.45 μm and stored in the fridge until usage. Filtering of the saliva was necessary to reduce 
the viscosity by removing glycoproteins and larger molecules without losing analyte molecules23. This procedure 
allows for preparing samples of a viscosity level comparable to serum by a very simple way suitable for PoC 
analysis.
The measurement buffer (MB) at a pH value of 7.4 was composed of 10 mM 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid (HEPES) sodium salt, 150 mM NaCl and 0.05% v/v Tween 20. Samples spiked 
with sHER2 were prepared by mixing the MB or dilutions of serum/saliva (diluted by the MB) with the sHER2 
antigen at a chosen concentration. Next, the nanoprobes were added to the sample solution. After an incubation 
time of 30 min at RT, the secondary antibodies diluted in MB (or volume-equivalent MB solutions for samples 
without added 2nd Abs) were added, and the whole sample was incubated for another 60 min at RT. The overall 
sample volume amounted to 240 µl, and the nanoprobe concentration was 10 pM. Measurements were conducted 
at a RMF amplitude of 10 mT and a rotational frequency of 1 kHz. These parameters are chosen for optimal 
measurement signals to detect target proteins by our specific nanoprobes10, 24. Phase lag differences were recorded 
with respect to a suitable reference value. For the measurements executed in buffer solution only, we employed 
reference samples comprising all reagents except of the analyte sHER2 molecules. In complex sample solutions of 
serum and saliva, the reference phase lag value was determined with samples containing no secondary antibod-
ies. Addition of the secondary antibodies only without analyte molecules did not result in a measurable signal. 
The errors of each measurement were determined by the standard deviations of the reference and the respective 
analyte-spiked samples and the error propagation law.
For determining the limit of detection, we defined a phase lag difference threshold. To that end, we added 
3-times the obtained error of the lowest spiked sHER2 analyte concentration (i.e. 0.125 nM) to the reference 
phase lag. Next, the assay results of the measured phase lag differences were fitted by a 4-parameter logistic fit 
model, and the limit of detection was obtained by using the threshold value in the fitting curve equation.
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